ロード中...
Switching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences
Riociguat is a novel soluble guanylate cyclase stimulator that is approved for the treatment of patients with pulmonary arterial hypertension (PAH) and patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent/recurrent CTEPH after pulmonary endarterectomy (PEA). A...
保存先:
| 出版年: | Respir Med Case Rep |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Elsevier
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5476463/ https://ncbi.nlm.nih.gov/pubmed/28652963 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.rmcr.2017.06.005 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|